Rojsajjakul, Teerapat
Hordeaux, Juliette J.
Choudhury, Gourav R.
Hinderer, Christian J.
Mesaros, Clementina
Wilson, James M. http://orcid.org/0000-0002-9630-3131
Blair, Ian A. http://orcid.org/0000-0003-0366-8658
Article History
Received: 10 July 2023
Accepted: 16 October 2023
First Online: 27 October 2023
Competing interests
: The authors declare the following competing interests: J.M.W is a paid advisor to and holds equity in iECURE, Scout Bio, Passage Bio, and the Center for Breakthrough Medicines (CBM). He also holds equity in the former G2 Bio asset companies. He has sponsored research agreements with Amicus Therapeutics, CBM, Elaaj Bio, FA212, former G2 Bio asset companies, iECURE, Passage Bio, and Scout Bio, which are licensees of Penn technology. C.J.H. holds equity in Scout Bio and a former G2 Bio asset company. J.M.W., C.J.H, and J.J.H, are inventors on patents that have been licensed to various biopharmaceutical companies and for which they may receive payments. I.A.B. has sponsored research agreements with Lexeo Therapeutics and Design Therapeutics. All other authors declare no competing interest.